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Abstract. Endoglin is a homodimeric membrane glyco- 
protein which can bind the 131 and 133 isoforms of trans- 
forming growth factor-13 (TGF-13). We reported previ- 
ously that endoglin is upregulated during monocyte 
differentiation. We have now observed that TGF-13 it- 
self can stimulate the expression of endoglin in cultured 
human monocytes and in the U-937 monocytic line. To 
study the functional role of endoglin, stable transfec- 
tants of U-937 cells were generated which overexpress 
L- or S- endoglin isoforms, differing in their cytoplas- 
mic domain. Inhibition of cellular proliferation and 
downregulation of c-myc mRNA which are normally 
induced by TGF-t31 in U-937 cells were totally abro- 
gated in L-endoglin transfectants and much reduced in 
the S-endoglin transfectants. Inhibition of proliferation 
by TGF-132 was not altered in the transfectants, in 
agreement with the isoform specificity of endoglin. Ad- 
ditional responses of U-937 cells to TGF-131, including 
stimulation of fibronectin synthesis, cellular adhesion, 
platelet/endothelial cell adhesion molecule i  (PECAM- 
1) phosphorylation, and homotypic aggregation were 
also inhibited in the endoglin transfectants. However, 
modulation of integrin and PECAM-1 levels and stimu- 
lation of mRNA levels for TGF-131 and its receptors 
R-I, R-II, and betaglycan occurred normally in the en- 
doglin transfectants. No changes in total ligand binding 
were observed in L-endoglin transfectants relative to 
mock, while a 1.5-fold increase was seen in S-endoglin 
transfectants. The degradation rate of the ligand was the 
same in all transfectants. Elucidating the mechanism by 
which endoglin modulates several cellular responses to 
TGF-131 without interfering with ligand binding or deg- 
radation should increase our understanding of the com- 
plex pathways which mediate the effects of this factor. 
T 
RANSFORMING growth factor-[3 (TGF-I3) is a mem- 
ber of a large family of proteins that has many bio- 
logical effects including regulation of cellular prolif- 
eration, differentiation and migration, extracellular matrix 
formation, and modulation of the immune response (Mas- 
sagu6 et al., 1994; Roberts and Sporn, 1993; Kingsley, 1994). 
In humans,  three isoforms have been identified, namely 
TGF[31, TGF132, and TGF[33. TGFI3s exert their function 
through binding to specific receptors, including  receptors 
type  I  (R-I),  type  II  (R-II),  betaglycan,  and  endoglin 
(Kingsley,  1994; Attisano  et  al.,  1994; Miyazono et  al., 
1994; Yingling  et  al.,  1995; L6pez-Casillas  et  al.,  1991; 
Cheifetz et al., 1992). Among these, the serine-threonine 
kinase receptor types I and II are necessary for all tested 
biological responses to TGF-13 (Attisano et al., 1994; Miya- 
zono et al., 1994; Yingling et al., 1995; Franzen et al., 1993; 
Bassing et al., 1994; Wrana et al., 1994; Laiho et al., 1991; 
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Wrana  et al.,  1992; C~ircamo et al.,  1994; Koenig et al., 
1994). Although the molecular mechanism of receptor ac- 
tivation  is  rather  complex, recent data  by Wrana  et  al. 
(1994) have provided some hints about the receptor I/recep- 
tor II interplay. Thus, TGF-[3 binding to the constitutively 
phosphorylated R-II is followed by recruitment of R-I into 
the complex, phosphorylation of R-I and propagation of 
the signal to downstream substrates (for a recent review 
see Yingling et al., 1995). 
Betaglycan forms heteromeric complexes with the sig- 
naling receptors type I and II and may function as a regu- 
lator of TGF-~ access to the signaling heteromeric kinase 
receptor complex formed by TGF-13 receptor components 
I  and  II  (L6pez-Casillas  et  al.,  1993; Moustakas  et  al., 
1993). It has been demonstrated that betaglycan increases 
the TGF-~ binding to the receptor II, which then recruits 
type I into the complex (L6pez-Casillas et al., 1993). Little 
is known about the possible role of endoglin in the TGF-[3 
signaling  pathways, although the heteromeric association 
between endoglin  and  the  signaling  receptors has been 
suggested  by  coimmunoprecipitation  experiments  (Ya- 
mashita  et al.,  1994; Zhang  et al.,  1996). Endoglin,  also 
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glycoprotein expressed by human endothelial cells (Gougos 
and  Letarte,  1988),  macrophages  (Lastres  et  al.,  1992; 
O'Connell  et al.,  1992), erythroid precursors  (Biihring  et 
al., 1991), syncytiotrophoblast of term placenta (Gougos et 
al., 1992), and stromal cells (St Jacques et al., 1994; Rokh- 
lin et al., 1995). The gene encoding endoglin has been lo- 
calized to human  chromosome  9 (Fermindez-Ruiz  et al., 
1993) and has been identified recently as the target gene 
for the  autosomal  dominant  vascular disorder  known as 
hereditary haemorrhagic  telangiectasia  type 1 (MacAllis- 
ter et al., 1994). Endoglin binds TGF-IM and TGF-133 with 
high  affinity  (kD=50  pM)  in  human  endothelial  cells 
(Cheifetz et al., 1992). Two different isoforms, L-endoglin 
and S-endoglin, with the capacity to bind TGF-13, but dif- 
fering in the amino acid composition of their cytoplasmic 
tails, have been characterized  (Gougos and Letarte, 1990; 
Bell6n et al.,  1993). The predominant  isoform L-endoglin 
contains  47 residues in the cytoplasmic domain,  whereas 
S-endoglin has only 14 amino acids with the seven residues 
proximal to the transmembrane  region being common to 
both  isoforms.  Interestingly,  betaglycan  and  L-endoglin 
share a region of high identity in the cytoplasmic tail with 
a high  content  (40%)  of potentially phosphorylated  Ser/ 
Thr residues (Gougos and Letarte, 1990; L6pez-Casillas et 
al., 1991; Wang et al., 1991; Mor6n et al., 1992). In fact, hu- 
man  endoglin  has been found to be constitutively phos- 
phorylated in endothelial cells and mouse fibroblast trans- 
fectants expressing either L-endoglin or S-endoglin (Lastres 
et al.,  1994).  Endoglin  is absent  from  peripheral  mono- 
cytes, but it is expressed by in vitro differentiated mono- 
cytes and following phorbol ester treatment of monocytic 
cell lines (Lastres et al., 1992). Here, we have analyzed the 
potential role of endoglin in modulating TGF-~ responses 
by transfecting cDNA encoding L- and S-endoglin into the 
U-937 monocytic line. 
Materials and Methods 
Cells and Stable Transfectants 
Human promonocytic U-937 cells were cultured in RPMI 1640 supple- 
mented with 10% heat inactivated FCS, 2 mM L-glutamine, penicillin (100 
U/ml), and gentamycin (25  ~g/ml) in a  5%  CO2 atmosphere at  37°C. 
Treatment of cells with recombinant human TGF-131 (R&D Systems, Ab- 
ingdon, UK) was performed at the concentrations and times indicated. 
Monocyte-derived macrophages were isolated by incubating peripheral 
blood mononuclear cells at 37°C, 5% CO2 and 100% humidity in autolo- 
gous plasma-coated plastic flasks (Lastres et al., 1992). Nonadherent cells 
were removed by washing with prewarmed Hunk's solution. Adherent 
cells were harvested with Hunk's medium containing 5 mM EDTA at 
37°C for 5  min. The phenotype of the adherent population was  >98% 
CDllb +, CDllc  +, CD31 +, and <3% CD3 +, CD2 +. 
U-937 transfectants expressing human L-endoglin or S-endoglin were 
generated by eotransfection of full-length eDNA encoding L-endoglin or 
S-endoglin in pcEXV and psV2neo at a ratio of 10:1, respectively (Bell6n 
et al., 1993). Transfections were performed by electroporation of 3 x  107 
cells in RPMI 1640 medium using a BTX 600 electroporator with 100 Ixg 
of plasmid DNA in 2-mm cuvettes. After selection in RPMI medium con- 
taining 10% FCS and 1.5 mg/ml of the antibiotic G418 (Sigma Chem. Co., 
St. Louis, MO), endoglin-positive cells were characterized by flow cytom- 
etry analysis. Parallel transfections with psV2neo alone yielded endoglin- 
negative mock transfectants. Pooled clones were used in biochemical and 
functional characterizations, except in quantitative PCR studies. No dif- 
ferences were observed between parental and mock transfectants in bio- 
chemical and functional studies. 
Flow Cytometry 
Ceils (5 x  105) were incubated with specific mAb for 30 rain at 4°C. After 
two washes with PBS, FITC-labeled F(ab')2 rabbit anti-mouse Ig (Dako- 
putts) was added and incubation proceeded for an additional period of 30 
rain at 4°C. Finally, cells were washed twice with PBS and their fluores- 
cence was estimated with an EPICS-CS (Coulter Cientifiea, M6stoles, 
Spain), using logarithmic amplifiers. Antibodies used were mAb 8Ell 
(anti-endoglin) (Lastres et al., 1992), HC1/6 (anti-platelet/endothelial cell 
adhesion molecule 1 [PECAM-1] 1) (Cabafias et al.,  1989),  HP1/7 (anti- 
VLA-4), (Shnehez-Madrid et al., 1986), PID6 (anti-VLA-5) (Tetios Phar- 
maceuticals,  Palo Alto, CA), and RR/1 (anti-intercellular adhesion molecule 
1  [ICAM-1])  (generous gift of Dr.  T.  Springer, Center for Blood Re- 
search, Boston, MA). 
Cell Surface Biotinylation 
Ceils were washed at 4°C with Hepes buffer (150 mM NaCI, 5 mM KCI, 
1.3 mM CaCl2,  1.2 mM MgC12, 10 mM Hepes, pH 7.4)  and allowed to 
equilibrate for 30 min at 4°C in the same buffer. Cells were washed again 
and resuspended at 2 x  106 eells/ml in Hepes buffer containing 0.5 mg/ml 
of sulfosuccinimidyl 6-(biotinamido) hexanoate (NHS-LC-biotin, Pierce 
Chem. Co., Rockford, IL). After incubation at 4°C for 2 h, the reaction 
was stopped by washing twice with Hepes buffer. For immunoprecipita- 
tion studies, cells were lysed in  lysis buffer (10 mM Tris-HC1,  pH 7.4, 
150 mM NaCI, 1 mM EDTA, 1% Triton X-100, 10 I~g/ml aprotinin, 10 p,g/ml 
pepstatin, 50 p,g/ml leupeptin, 1 mM benzamidine and 1 mM PMSF), for 
40 min at 4°C. The lysates were centrifuged for 15 rain at 12,000 g and the 
supernatants were precleared for 4 h with protein G coupled to Sepharose 
(Pharmacia Biotech, Barcelona, Spain) at 4°C. Specific immunoprecipita- 
tions of the precleared lysates were carried out in the presence of 10 p.g/ml 
of the mAb 44G4 (anti-endoglin) (Gougos and Letarte, 1988), using pro- 
tein G coupled to Sepharose. After overnight incubation at 4°C, immuno- 
precipitates were isolated by centrifugation and washed twice with lysis 
buffer at 4°C.  Immune complexes were subjected to SDS-PAGE on a 
7.5 % acrylamide gel under nonreducing conditions and electrotransferred 
to nitrocellulose. Filters were blocked with 5% powder milk in PBS for 1 h 
and then incubated with 2 p,g/ml of streptavidin conjugated to horseradish 
peroxidase (Pierce Chem. Co.) for 2 h at room temperature. Biotinylated 
endoglin was detected using an Enhanced ChemiLuminescence system 
(Amersham Ib6rica S.A., Madrid, Spain). 
RNA Preparation and Northern Blot Analysis 
Total cellular RNA was isolated using guanidinium thiocyanate/phenol/ 
chloroform (Chomczynski and Sacchi, 1987). RNA samples (10 Ixg) were 
denatured and then fractionated in 1.1% agarose/formaldehyde gels and 
blotted onto nitrocellulose. Membranes were hybridized in 50%  forma- 
mide at 42°C with excess 3Zp-labeled probes, washed under highly strin- 
gent conditions (0.2  ×  SSC and 0.5%  SDS at 52°C), and radiolabeled 
bands were detected with a PhosphorImager 410A and ImageQuant soft- 
ware (Molecular Dynamics, Sunnyvale, CA). The probes used were the 
2.2-kb EcoRI insert of endoglin in pcEXV-EndoS (Bell6n et al., 1993) and 
the 1.5-kb  Clal-EcoRI fragment of pMA413 plasmid which contains the 
third exon of c-myc (Dalla Favera et al., 1982). 
Analysis of TGF-fll and Its Receptors by 
Quantitative PCR 
U-937 transfectants were treated with or without 100 pM TGF-131 for 72 h. 
Cells were washed and total cellular RNA was extracted (Chomczynski et 
at., 1987). Before reverse transcription the concentration of RNA was es- 
timated in two independent determinations and at two different dilutions, 
as this is a crucial parameter in the quantitative analysis of mRNA expres- 
sion (Murphy et al., 1990). The integrity of oligo(dT)-synthesized eDNA 
was confirmed by [3-actin PCR. The oligonucleotides used for the amplifi- 
cation of actin, TGF-131, TGF-13 receptor II, endoglin and betaglycan, and 
the conditions for exponential amplification have been described previ- 
ously (Jindal et al., 1995). Specific primers and an internal probe for TGF-[3 
receptor I (ALK-5) were chosen from the published sequence (Franz6n et 
al., 1993): primer A (5'-AATFCCTCGAGATAGGCCGT-3') correspond- 
1. Abbreviations used in this paper: ICAM-1, intercellular adhesion mole- 
cule 1; PECAM-1, platelet/endothelial cell adhesion molecule 1. 
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corresponding to the complement of bp 530-511  and the internal probe 
(5'-TACAGTAGTFGGAAGTrCTA-3') complementary to the bp 421- 
402. Briefly, eDNA was serially diluted in water to concentrations ranging 
from 400 ng to 0.16 ng of corresponding RNA per sample and the PCR re- 
action (100 Vd) performed in 10 mM Tris-HCl, pH 8.3, containing 50 mM 
KC1,1.5 mM MgCI2, 0.001% gelatin, 200 ~M dNTPs, 0.5 pg each of 5'- and 
3'- primers and 0.25 U  of Taq DNA polymerase (Pharmacia, Montreal, 
Canada). The amplification profile involved preincubation at 98°C for 5 rain, 
denaturation at 94°C for 75 s, primer annealing at 58°C for 75 s and exten- 
sion at 72°C for 2 rain. The PCR reaction is considered quantitative if an 
exponential range is obtained with each sample; this requires 28 cycles for 
13-actin, TGF-I31, R-I, R-II and endoglin, and 30 cycles for betaglycan (Jindal 
et al., 1995; Zhang et al., 1996).  A  10-p.l aliquot of PCR reaction mixture 
was  electrophoresed  in  4-20%  gradient  polyacrylamide  gels  in  Tris- 
borate/EDTA buffer (Novel Experimental Technology, San Diego, CA). 
Gels were stained with ethidium bromide and photographed. Gels were 
also transferred to nylon membranes and hybridized with the specific in- 
ternal probes 3'end-labeled with Digoxigenin-ll-ddUTP; the DIG-labeled 
oligonucleotides were detected by chemiluminescence with Lumigen PPD 
according  to  manufacturer's instructions (Boehringer  Mannheim, Bio- 
chemica, Montreal, Canada). Membranes were then exposed to Standard 
X-ray film for 2-5 min; each band was scanned on a Densitometer model 
300A (Molecular Dynamics Co.). Background under each band was auto- 
matically subtracted and the densitometric units were recorded and plot- 
ted vs the corresponding concentration of RNA to ascertain the exponen- 
tial range of the amplification as described previously (Jindal et al., 1995; 
Zhang et al., 1996). 
Proliferation Assays 
U-937 cells were cultured in flat bottomed 96-well plates (Costar, Cam- 
bridge, MA) at 3 ×  104 cells/well in RPMI with 10% FCS in the absence or 
in the presence of TGF-I31 for the times indicated, the last 6 h in the pres- 
ence of 1  i~Ci per well of (3H-methyl)-thymidine (3H-TdR, Amersham, 
UK). Cells from triplicate samples were collected using a harvester (Ska- 
tron, Norway) and 3H-Thy incorporation into DNA was measured in a liq- 
uid scintillation counter. 
Western Blot Analysis 
U-937 cells were cultured at a density of 5 ×  105 cells/ml in RPMI contain- 
ing 10%o FCS. In some experiments, cells were treated with either 500 pM 
TGF-13 for 72 h or 10 ng/ml of PMA for 48 h. Cells were collected by cen- 
trifugation, lysed with lysis buffer and extracts corresponding to 2  ×  106 
cells were subjected to SDS-PAGE on 7.5% polyacrylamide gels under 
nonreducing conditions. Proteins were electrophoretically transferred to 
nitrocellulose membranes (Millipore Corp., Bedford, MA). Filters were 
blocked with PBS containing 5% milk powder for 1 h. Specific immunode- 
tection  was carried  out by incubation with mAb 44G4  (anti-endoglin) 
overnight, followed by peroxidase-conjugated goat anti-mouse Ig at room 
temperature. The presence of endoglin was revealed using a chemilumi- 
nescence assay (ECL detection kit, Amersham Ib6rica). Quantitative esti- 
mations were performed by densitometry of the autoradiograms using the 
ImageOuant software (Molecular Dynamics). 
Metabolic Labeling of PECAM-I 
U-937 cells were incubated with or without 500 pM of TGF-[31 for 20 h. 
Then, cells were preincubated for 30 min at 37°C in phosphate-free or me- 
thionine/cysteine-free RPMI medium containing 10% dyalized FCS. Me- 
dium was removed, fresh medium containing 100  p.Cilml of [3ZP]ortho- 
phosphate or 50  p.Ci/ml of [35S]methionine/cysteine (ICN  Biomedicals, 
Inc., Costa Mesa, CA) was added and the cells were metabolically labeled 
at 37°C in a 5% CO2 atmosphere for 4 h with or without 500 pM of TGF-~I. 
Cells were then collected by centrifugation, washed twice at 4°C with PBS, 
and lysed in 250 Ixl of lysis buffer containing a phosphatase inhibitor cock- 
tail (1 mM orthovanadate, 1 mM sodium molybdate, and 1 mM sodium 
fluoride). The lysates were centrifuged for 15 min at 12,000 g and the su- 
pernatants were precleared for 4 h with protein G-Sepharose (Pharmacia 
Biotech) at 4°C. Specific immunoprecipitations of the precleared lysates 
were carried out in the presence of mAb HC1/6 (anti-PECAM-1), using 
protein G-Sepharose. After overnight incubation at 4°C, immunoprecipi- 
tates were isolated by centrifugation, washed twice with lysis buffer at 4°C, 
and then subjected to SDS-PAGE on a 7.5% acrylamide gel under nonre- 
ducing conditions. Detection of the 32p-labeled PECAM-1 was revealed 
with a PhosphorImager 410A and ImageQuant software (Molecular Dy- 
namics). Detection of 3SS-labeled  bands was revealed with standard auto- 
radiography (Kodak). 
Cellular Aggregation Assays 
U-937 transfectants were cultured in flat-bottom 96-well plates (Costar) at 
3 ×  104 cells/well and incubated either in the absence or in the presence of 
500 pM of TGF-131 for 24 h in RPMI containing 10% FCS at 37°C and 5% 
CO2 in triplicate wells. Ceil aggregates formation was visualized on the 
plate with a phase contrast microscope (Nikon Diaphot, Tokyo, Japan). 
Cellular Adhesion Assays 
Adhesion to uncoated surfaces was performed by incubating U-937 trans- 
fectants (5  ×  104 ceils/well) either in the absence or in the presence of 
500 pM of TGF-131. For cellular adhesion to fibronectin-coated surfaces, 
96-well plates were coated with 1 i~g/cm  2 of human fibronectin in 100 I~1 
(Sigma Chem. Co.) at 37°C for 1 h. Wells were washed three times with 
PBS and incubated with 1% BSA in PBS at 37°C for an additional period 
of 1 h; then, wells were rinsed three times with PBS. Cells treated with 
TGF-I31 at 500 pM for 24 h were washed, resuspended in RPMI contain- 
ing 1% BSA and 10 mM Hepes at a concentration of 5 ×  105 cells/ml, and 
100  Ixl of the cell suspension were added to each well. Incubations were 
carried out for I h at 37°C in triplicate samples. 
At the times indicated (see figure legends for details), culture medium 
was  removed and  the wells gently washed twice  with  PBS  containing 
0.9 mM CaC12 and 0.5 mM MgC12. Cells attached were fixed overnight 
with 1% glutaraldehyde in PBS at room temperature. Plates were rinsed 
three times and cells stained with 0.1% toluidine blue during 2 h at room 
temperature. Additionally, wells were rinsed three times with PBS and 
cell associated dye was extracted with 100 V,1 of 10% acetic acid. The opti- 
cal density in the wells was measured at 628 nm with a Multiscan Biochro- 
matic (Labsystem, Helsinki, Finland). Percentage of cells attached was 
calculated using a calibration curve. 
Fibronectin Production 
U-937 transfectants were incubated in the presence of 500 pM TGF-131 in 
RPMI 10% FCS at 37°C under 5%  COz atmosphere for the times indi- 
cated. Metabolic labeling was carried out for the last 4 h of treatment in 
2 ml of serum-free medium (ICN Biomedicals, Barcelona, Spain) contain- 
ing 50 p.Ci/ml of [3SS]methionine/cysteine (Trans-35S  label, ICN Biomedi- 
cats) at a  density of 2.5  ×  106 ceUs/ml. Culture supernatants were col- 
lected,  centrifuged at  12,000  g  for 5  min and precleared  for 4  h  with 
Sepharose in the presence of 0.1% Triton X-100 and 1 mM PMSF. Spe- 
cific precipitation  of soluble fibronectin was carried  out with 50  wl of 
packed gelatin-Sepharose (Pharmacia Biotech) at 4°C overnight. Precipi- 
tates were isolated by centrifugation, washed twice with PBS at 4°C and 
subjected to SDS-PAGE on a 6% acrylamide gel under reducing condi- 
tions. Detection of radiolabeled bands was revealed with standard autora- 
diography (Kodak). 
Specific Binding of 125I-TGF-[31 
U-937  ceils  expressing endoglin  and  control  mock  transfectants were 
washed in PBS and equilibrated for 40 rain in RPMI 1640 containing 25 mM 
Hepes buffer, pH 7.0, and 2 mg/rrd BSA. Between 4 and 7 ×  106 cells/sam- 
ple were incubated for 4 h at 4°C with 25-250 pM of 12SI-TGF-131 with or 
without a  40-fold excess of competing unlabeled TGF-131  and in a  final 
volume of 1.0 ml in siliconized Eppendorf tubes. 125I-TGF-131 (800-2,000 
Ci/mmol) was either kindly provided by Celtrix Pharmaceuticals (Santa 
Clara,  CA)  or  purchased from Amersham Ibtrica.  Cells were  washed 
twice in a 0.05-M Hepes buffer, pH 7.5, containing 128 mM NaCI, 5 mM 
KCI, 5 mM MgSO4, 1.2 mM CaC12 (buffer A) supplemented with 2 mg/ml 
BSA, and washed once and resuspended in 1.0 ml of buffer A, essentially 
as  described previously (Massagut, 1987).  Cell-associated radioactivity 
was estimated in a gamma counter. 
Receptor Affinity Labeling 
Affinity labeling assays were basically performed as described (Massagut, 
1987).  Briefly, U-937 ceils expressing S-endoglin or L-endoglin and mock 
transfectants were incubated in Hepes buffer containing 0.1% BSA with 
50-250 pM of 125I-TGF-131 for 4 h with or without a 50-fold excess of com- 
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was cross-linked with 0.30 mM disuccinimidyl suberate (Pierce Chemical 
Co.) in Hepes buffer for 15 min at 4°C. Cells were washed four times and 
solubilized in lysis buffer. The total  extracts  were directly  subjected  to 
SDS-PAGE analysis or to specific immunoprecipitations  with mAb 44G4 
(anti-endoglin). Detection of the 125I-labeled  receptors was revealed using 
a Phosphorlmager  410A (Molecular Dynamics). 
Degradation of IzS  I-  TGF-fl  I Assays 
Degradation  assays were basically performed as described (Frolik et al., 
1984). Briefly, U-937 transfectant  cells were incubated  at 37°C for 1 h in 
the presence of 100 pM of ~zSI-TGF-131 at 5 × 106 cells/ml in DMEM me- 
dium containing 0.1%BSA, 25 mM Hepes, pH 7.4. Cells were washed ex- 
tensively with fresh medium and triplicate aliquots (2.5 ×  106 cells) were 
transferred to new tubes and incubated for an additional period of 30 min, 
1 h or 2 h at 37°C. As a control,  some aliquots were maintained  on ice 
(time = 0). At the end of each time interval, cells were pelleted by centri- 
fugation at 700 g for 3 min at 4°C and the supernatants were removed, A1- 
iquots of 500 p,1 were precipitated  with 10% TCA on ice. Soluble and in- 
soluble material were separated by centrifugation at 12,000 g at 4°C for 10 
rain. For each incubation time, cell-associated radioactivity, total radioac- 
tivity in supernatants and TCA soluble radioactivity were estimated in a 
gamma counter (LKB, Bromma, Sweden). Total radioactivity present in 
the samples (cell associated plus supernatant) was considered as 100%. 
Results 
TGF-~ Upregulates  Endoglin Expression in 
Monocytic Cells 
We have previously reported that endoglin is upregulated 
during  monocyte  differentiation  (Lastres  et  al.,  1992). 
Since TGF-~ is able to synergize with other factors in mac- 
rophage differentiation (De Benedetti et al., 1990; Testa et 
Figure 1.  Effect of TGF-~3 on the expression of endoglin by monocytic cells. (A) U-937 cells were incubated in the absence (C) or in the 
presence of 500 pM TGF-IM for 24, 48, and 72 h, respectively. The reactivity of 8El 1 (anti-endoglin) mAb was assayed by flow cytome- 
try. The broken vertical line represents the gate determined in the control staining with an irrelevant mAb. (B) Human peripheral 
monocytes freshly harvested or incubated with or without 500 pM TGF-131 for 24 h were analyzed for endoglin expression by flow cy- 
tometry as described in A. (C) RNA was prepared from monocytes and U-937 cells incubated with or without 500 pM TGF-131 for the 
times indicated. Endoglin transcripts of 3.4 kb were detected by Northern blot analysis. The blots were also stained by ethidium bromide 
to visualize the 28S ribosomal RNA. (D) Peripheral monocytes were cultured in the presence of a neutralizing antibody to TGF-[3, a 
control antibody, or exogenous TGF-~. At the times indicated, the expression of endoglin was estimated by flow cytometry using an 
anti-endoglin mAb. Similar results were obtained when using a serum-free medium. The mean of three different experiments  _+ SD is shown. 
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et  al.,  1987),  we wondered  whether  TGF-13 would  affect 
expression  of endoglin.  Low levels  of endoglin were  de- 
tected on the surface of U-937 cells; however, when U-937 
cells were cultured in the presence of TGF-[3 endoglin ex- 
pression was clearly increased up to 3-4-fold after 72 h  of 
treatment  (Fig.  1  A).  Addition  of exogenous  TGF-[3  to 
peripheral  blood monocytes was also able  to increase  by 
4-5-fold the expression  of endoglin after 24 h  in culture 
(Fig.  1 B). This regulatory effect was evident not only at 
the cell surface, but also when the levels of specific mRNA 
transcripts  were  analyzed in  both  monocytes and  U-937 
Figure 2.  Characterization of U-937 endoglin transfectants. U-937 cells were transfected with L- or S-endoglin cDNA or with vector 
alone (Mock) and the expression of the endoglin molecule analyzed. (A) Analysis by cytofluorometry of the endoglin present at the cell 
surface. Cells  were stained by indirect immunofluorescence with an anti-endoglin mAb. The mean fluorescence intensities  of mock, 
L-endoglin, and S-endoglin transfectants were 7, 163, and 191, respectively. (B) Immunoprecipitation analysis.  Cells were surface la- 
beled with biotin, lysed, and immunoprecipitated with anti-endoglin mAb. Samples were electrophoresed on a 7.5% acrylamide gel un- 
der nonreducing conditions, transferred to nitrocellulose, and the biotinylated endoglin detected using a chemiluminescence assay. (C) 
Western blot analysis.  Extracts from untreated, TGF-131-treated, or PMA-treated parental U-937 cells and L-endoglin or S-endoglin 
transfectants were electrophoresed and transferred to nitrocellulose membranes. The presence of endoglin was revealed with anti-endo- 
glin mAb using a chemiluminescence assay. (D) The autoradiogram shown in C was subjected to densitometric analysis  using the Im- 
ageQuant software. Relative levels of endoglin in parental U-937 cells and L-endoglin (L-Endo) or S-endoglin (S-Endo) transfectants 
are shown. 
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ble of mediating the upregulation of endoglin observed on 
monocytes in culture (Lastres et al., 1992) as this was pre- 
vented by the  addition  of a  neutralizing polyclonal anti- 
body to TGF-131  (Fig. 1 D). Similar results were obtained 
when peripheral blood monocytes were cultured in serum- 
free medium (data not shown), suggesting that endogenous 
production and/or activation of TGF-[3 by the monocytes 
might  be  responsible  for  the  upregulation  of  endoglin. 
Since macrophages are able to synthesize this ligand (As- 
soian et al., 1987), it is tempting to speculate the involve- 
ment of autocrine TGF-131  in the upregulation of its own 
receptor. These results demonstrate that TGF-13 induces 
the expression of endoglin in monocytic cells. 
Endoglin Expression Interferes with Cellular 
Responses to TGF-fl 
To study the role of endoglin in TGF-13 signaling, L-endo- 
glin  and  S-endoglin  transfectants  were  generated  in  the 
U-937 human monocytic line. Fig. 2 A  demonstrates that 
both forms of endoglin are expressed at high levels on the 
surface of U-937 transfectants, as determined by flow cytom- 
etry analysis. Mean fluorescence intensity values indicated 
that the level of endoglin expressed on L- and S-endoglin 
transfectants were 23-27  times that  of mock or parental 
cells.  Immunoprecipitation  analysis  revealed  a  170-kD 
dimer (L-endoglin) or a 160-kD dimer (S-endoglin) specif- 
ically recognized by mAb 44G4 (Fig. 2 B). The level of re- 
combinant  endoglin  expressed  in  the  transfectants  was 
also analyzed by Western blot (Fig. 2  C) and found to be 
significantly higher than that induced in U-937 cells treated 
with TGF-13 or phorbol esters (3-4-fold) (Fig. 2 D). Differ- 
ences  observed  in  the  levels  of  endoglin  expressed  by 
transfectants  relative to  control when  estimated by flow 
cytometry (23-27) or Western blot (13-16) analyses, might 
be explained by methodological differences between these 
immunodetection techniques. Several biological responses 
of monocytes to TGF-13,  which had been described previ- 
ously,  were  analyzed  in  the  endoglin  transfectants  and 
compared to that of parental or mock-transfected lines. 
Cellular Proliferation and c-myc Regulation 
As demonstrated previously, 24 h incubation with TGF-131 
or -132 inhibit the proliferation of U-937 cells in a dose-depen- 
dent  manner  (Lastres  et  al.,  1994;  Fig.  3  A).  However, 
L-endoglin transfectants were not inhibited at all by TGF-131 
while  S-endoglin  transfectants  were  only partially inhib- 
ited  (Fig. 3 A). The decrease in proliferation induced by 
TGF-132  was  not  altered  in  the  endoglin  transfectants, 
which is in agreement with the known binding specificity 
of endoglin  for the  131  isoform and  not  the  [32  isoform 
(Cheifetz et al., 1992). 
In U-937 cells, a decrease in c-rnyc transcript levels is as- 
sociated with inhibition of proliferation induced by TGF-131 
(Lastres et al.,  1994).  Fig. 3,  B  and  C  show a  substantial 
Figure3. Effects of TGF-131 on cellular proliferation and expres- 
sion  of c-myc transcripts  in  U-937  endoglin  transfectants.  (A) 
Transfectants were incubated with either TGF-IM or TGF-132 at 
different concentrations.  The proliferative capacity  of the cells 
was measured after 24 h in culture  by [3H]thymidine incorpora- 
tion. The absolute cpm of untreated mock, L-endoglin and S-endo- 
glin transfectants were 55,307 -+ 5,906, 50,132 -+ 4,546, and 60,333 -+ 
3,399, respectively.  The mean  -+  SD  of three different  experi- 
ments performed in triplicate  samples is shown. (B) Effect of en- 
doglin expression on the c-myc levels detected in the presence of 
500 pM TGF-IM. Transfectants were incubated with or without 
500 pM TGF-IM for the times indicated  and the levels of specific 
transcripts  of c-myc mRNA detected by Northern blot analysis. 
RNA blots were stained  with ethidium bromide to visualize the 
28S rRNA. The levels of c-myc mRNA were quantitated by den- 
sitometric  analysis using the ImageQuant software  and are illus- 
trated in C. 
The Journal of Cell Biology,  Volume 133, 1996  1114 Figure 4.  Effect of TGF-131 on cell adhesion receptors and fibronectin  synthesis of U-937 endoglin transfectants. (A) Effect of endoglin 
expression on the TGF-IM-induced  homotypic aggregations. Cell transfectants were incubated either in the absence or in the presence 
of 500 pM TGF-131 for 24 h and aggregate formation was visualized by phase contrast microscopy.  (B) Immunoprecipitation  analysis of 
pECAM-1. Cell transfectants were incubated either in the absence or in the presence of 500 pM TGF-131 for 20 h, metabolically  labeled 
with [35S]methionine/cysteine and lysed as described in Materials and Methods. Lysates were immunoprecipitated  with mAb HC1/6 to 
PECAM-1 and protein G-Sepharose. Samples were subjected to SDS-PAGE and standard autoradiography. (C) Effect of endoglin ex- 
pression on the TGF-131 dependent phosphorylation of PECAM-1. Cell transfectants were incubated either in the absence or in the 
presence of 500 pM TGF-131 for 20 h, metabolically  labeled with [32p]orthophosphate  and lysed as described in Materials and Methods. 
Lysates were immunoprecipitated  with protein G-Sepharose in the presence of the mAb HC1/6 to PECAM-1. Samples were subjected 
to SDS-PAGE followed by detection of radiolabeled bands on the gel with the use of a Phosphorlmager 410. (D) Effect of endoglin ex- 
pression on the TGF-131-induced fibronectin synthesis.  Cell transfectants were incubated in the presence of 500 pM TGF-131 for the 
times indicated and metabolically  labeled with [35S]methionine/cysteine for 4 h. Soluble fibronectin was precipitated from the superna- 
tants using gelatin-Sepharose. Samples were subjected to SDS-PAGE followed by detection of radiolabeled bands by autoradiography. 
(E) Effect of endoglin expression on the TGF-131-induced  cellular adhesion to fibronectin-coated  surfaces. U-937 transfectants were in- 
cubated either in the absence or in the presence of 500 pM of TGF-131 in RPMI containing 10% FCS. After 24 h in culture, cells were 
washed, resuspended in RPMI containing  1% BSA and 10 mM Hepes, and incubated in fibronectin-coated  wells. After 1 h, culture me- 
dium was removed and the wells gently washed twice. Cells attached were fixed overnight with 1% glutaraldehyde and stained with 
0.1% toluidine blue. Cell-associated dye was extracted with 10% acetic acid and the optical density in the wells was measured at 628 nm 
with a Multiscan Biochromatic. The mean of triplicate samples  +-- SD is shown.  (F) Effect of endoglin expression on the TGF-131- 
induced cellular adhesion to uncoated surfaces. U-937 transfectants were incubated either in the absence or in the presence of 500 pM of 
TGF-131 on uncoated 96-well plates. At the times of treatment indicated, culture medium was removed and the wells gently washed 
twice. The number of cells attached were estimated as described in C. downregulation of these transcripts in mock transfectants 
6 h after addition of TGF-131. In the L-endoglin transfec- 
tants, a 2-3-fold increase in the basal level of c-myc tran- 
scripts was observed and these levels were unaffected by 
the addition of ligand. The S-endoglin transfectants also 
showed higher basal levels of c-myc transcripts; however, a 
decrease in  these  levels could be induced by treatment 
with TGF-131. Thus, S-endoglin transfectants show an in- 
termediary response in terms of both c-myc downregula- 
tion and inhibition of cellular proliferation. However, the 
presence of L-endoglin in U-937 cells totally suppressed 
c-myc downregulation and inhibition of proliferation. Taken 
together, these results suggest that endoglin expression in- 
terferes  with  the  inhibition  of cellular  proliferation in- 
duced by TGF-IM. 
PE  CAM- I  Upregulated Expression, Phosphorylation, 
and Homotypic Aggregation 
We have previously demonstrated that TGF-[31 induces 
the expression of PECAM-1 in U-937 cells and its activa- 
tion by phosphorylation which in turn induces the homo- 
typic aggregations of these cells (Lastres et al.,  1994). In 
the current study, we noted that TGF-131 was unable to in- 
duce the aggregation of the endoglin transfectants while it 
stimulated that of the parental cells or mock transfectants 
(Fig. 4 A). We thus assessed whether the inability to form cel- 
lular aggregates was due to a lack of induction of PECAM-1 
or to an inability to phosphoryla*,e this molecule. We ob- 
served a  2-3-fold increase in the level of PECAM-1  fol- 
lowing treatment of parental U-937 cells with TGF-131 as 
measured by flow cytometry analysis (Lastres et al., 1994). 
A similar level of induction was seen with the mock trans- 
fectants,  and  the  S-  and L-endoglin transfectants  which 
showed a 2.7-, 3.3-, and 2.6-fold increase of PECAM-1 ex- 
pression, respectively (Table I). Fig. 4 B confirms that the 
presence of endoglin does not alter the ability of the cells 
to upregulate PECAM-1  revealed as  a  protein of Mr = 
130,000 by immunoprecipitation of 35S-labeled cells. How- 
ever, no phosphorylated PECAM-1 could be detected by 
immunoprecipitation with specific antibodies from L- or 
S-endoglin transfectants, whereas it could be readily ob- 
served in mock transfectants (Fig. 4 C). Thus, although the 
presence of endoglin does not impair the upregulation of 
PECAM-1  in response to TGF-IM, it prevents its phos- 
phorylation and the induction of homotypic aggregation. 
Induction of  Fibronectin Synthesis 
In several cell types, TGF-[3 is capable of inducing the syn- 
thesis of fibronectin (Massagu6,  1990). We thus assessed 
the ability of U-937 cells and their endoglin transfectants 
to synthesize this extracellular matrix component. Fig. 4 D 
illustrates that fibronectin synthesis is induced by TGF-~I 
in mock transfectants, particularly after 24 h of treatment. 
By contrast, transfectants expressing either L- or S-endo- 
glin were less responsive to ligand. Thus, endoglin inter- 
feres with the ability of U-937 cells to synthesize fibronec- 
tin in response to TGF-[31. 
Cell Adhesion Receptors 
It has been observed previously that treatment with TGF-131 
enhances  the  attachment  of  U-937  cells  to  fibronectin 
through the ct5131 integrin receptor (Bauvois et al.,  1992). 
Thus, we wondered whether binding of these receptors to 
a  fibronectin-coated  surface  was  affected  in  endoglin 
transfectants.  Mock  transfectants  showed  a  marked  in- 
crease in cellular adhesion capacity, while endoglin trans- 
fectants showed a much reduced stimulation of adhesion 
by TGF-131 (Fig. 4 E). In addition, the ability of endoglin 
transfectants to adhere to uncoated plates was totally in- 
hibited, whereas mock transfectants showed a time-depen- 
dent increase in adhesion (Fig, 4 F). These results suggest 
that membrane receptors for fibronectin and possibly for 
other extracellular matrix components are affected in en- 
doglin transfectants. 
TGF-IM has been shown to upregulate the synthesis of 
t~5131 integrin and to downregulate the expression of Ot4[~  1 
and of intercellular adhesion molecule 1 (ICAM-1) in mono- 
cytic cells (Bauvois et al., 1992; Wahl et al., 1993; Lastres et 
al.,  1994).  We confirmed these results here and noted no 
difference between endoglin and mock transfectants in the 
modulation of their integrins in response to TGF-131.  A 
1.5-1.7-fold increase in  Ot5[~  1 integrin was observed com- 
pared  to  a  1.3-1.7-fold  decrease  in  tx4131 integrin  and 
ICAM-1 in all groups following treatment with ligand (Ta- 
ble I). Thus, modulation of the levels of adhesion recep- 
tors was not influenced by the presence of endoglin. How- 
ever,  activation of et5131 integrin,  which  is  necessary for 
adhesion to fibronectin, might not occur in the endoglin 
transfectants. 
TGF-[31 Upregulates Itself  and Its Receptors 
in U-937 Cells and Endoglin Overexpression  Does Not 
Alter the Response 
To determine whether the upregulation of endoglin ob- 
served in Fig. 1 could be extended to other TGF-13 recep- 
tors,  we  performed  quantitative  RT-PCR  analysis  on 
U-937 cells treated with or without 100 pM TGF-[31 for 
72 h. To facilitate the comparison of receptors levels be- 
tween  the  endoglin  transfectants  and  mock or parental 
groups, relative levels of RNA were estimated by quanti- 
tative 13-actin RT-PCR. The 318-bp PCR product that spe- 
cifically hybridized to the 13-actin probe was estimated at 
different concentrations of corresponding RNA  and the 
exponential range of amplification determined. Fig. 5 A il- 
lustrates  the levels of 13-actin mRNA  at a  concentration 
within this exponential range (0.5 ng/sample). In all exper- 
iments, the exponential range of detection of each of the 
receptors was  determined and corrections made for the 
relative levels of RNA in these samples. Fig. 5 A  shows a 
Table 1. Effect of TGF-[3 on the Expression of Cell Adhesion 
Receptors 
Mock  L-Endoglin  S-Endoglin 
TGF-[3  -  +  -  +  -  + 
PECAM-1  22(100)  60 (273)  20(100)  52 (260)  18 (100)  60 (333) 
a4131  25 (100)  15 (60)  22 (100)  16 (73)  20(100)  16(80) 
asl3~  18 (100)  31 (172)  17 (100)  27 (159)  17 (100)  26 (153) 
ICAM-1  17(100)  13(76)  13(100)  10(77)  16(100)  10(63) 
U-937 transfectants  were treated with or without 500 pM TGF-[3 for 24 h and stained 
with mAb to cell adhesion receptors.  Values represent the mean channel fluorescence 
intensity obtained by flow cytometry.  Expression levels relative to that of untreated 
transfectants  (arbitrary value =  100) are shown in parentheses. 
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Fig. 5 B  demonstrates the exponential range reached and 
how the stimulation of receptor expression was determined. 
Receptor I mRNA expression, as estimated in the expo- 
nential range of amplification of a specific 224-bp product, 
was stimulated ninefold by treatment of U-937 cells with 
TGF-[31. Receptor II mRNA level measured as a  261-bp 
product was upregulated 14-fold, while the 364-bp specific 
betaglycan PCR product was stimulated fourfold (Fig. 5, A 
and B). Thus, TGF-131  can upregulate not only endoglin, 
but also R-I, R-II, and betaglycan in U-937 cells. 
Figure 5.  TGF-[31 upregulates itself  and its  receptors and  the 
presence of endoglin  does not alter these responses.  (A) Mock 
(M), short endoglin ($6 and $10 clones), and long-endoglin  (L8) 
U-937 transfectants were incubated with (+) or without  (-) 100 
pM TGF-131 for 72 h at 37°C. RNA was extracted and RT-PCR 
was carried out to analyze the expression  of TGF-~I and endo- 
glin using 10 ng/lane  or at the concentrations  indicated  for R-I, 
R-II, and betaglycan.  Quantitation of ~-actin  mRNA was per- 
formed on  each  sample by  RT-PCR to  estimate  the  relative 
amount of RNA present. The single concentration shown here 
(0.5 ng RNA/sample) was within the exponential range. 10 ~1 of 
each PCR  mixture was  fractionated by electrophoresis,  trans- 
ferred, hybridized  with digoxigenin-labeled  probes, and specific 
bands detected by chemiluminescence.  Expression of R-I, R-II, 
and betaglycan mRNA was analyzed at three different concentra- 
tions and is illustrated for Mock, $6, and L8 transfectants.  (B) Ex- 
ample of the quantitative measurement by RT-PCR of the in- 
crease in TGF-[3 receptors expression observed after treatment of 
cells with (0) or without (O) 100 pM TGF-I31  is shown for the mock 
transfectants.  After RT-PCR and hybridization  with the specific 
probes as shown in A, each band was scanned  and the densito- 
metric units were plotted vs the corresponding RNA concentra- 
tion. The lines drawn represent the exponential range of amplifi- 
cation and the increase in mRNA levels is calculated  within this 
range for R-I, R-II, and betaglycan. 
As it was reported previously that TGF-131 could upreg- 
ulate  its own expression in macrophages (Assoian et al., 
1987;  McCartney-Francis  et  al.,  1990),  we  also  analyzed 
whether it could also do so in U-937 cells. Fig. 5 A  illus- 
trates that the specific 178-bp TGF-[31 PCR product is in- 
creased substantially after TGF-131 treatment. We then an- 
alyzed  whether  transfection  of  endoglin  in  U-937  cells 
could alter the upregulation of TGF-131  and its receptors. 
Fig. 5 A  demonstrates that mock transfectants, two inde- 
pendent clones of S-endoglin ($6 and $10) and one clone 
of L-endoglin (L8) transfectants, all responded similarly to 
TGF-[31 treatment. Data were analyzed similarly to those 
shown in Fig. 5 A  and revealed no significant alteration by 
transfected  endoglin  of the  stimulation  of mRNA levels 
for  TGF-[31  and  its  receptors  in  U-937  cells.  Unfortu- 
nately, the possible TGF-[31 mediated endoglin upregula- 
tion in endoglin transfectants could not be determined due 
to the interference of the elevated background levels of re- 
combinant protein and mRNA. 
Effect of  Endoglin Expression on TGF-[3 Binding 
and Degradation 
Given the modulatory effect of endoglin expression on the 
TGF-[3  signaling,  it  was  of  interest  to  analyze  whether 
ligand binding to the specific receptors or degradation of 
TGF-[3 were affected. First, TGF-[31 binding to cell trans- 
fectants  was  carried  out  at  different  concentrations  of 
ligand. Fig. 6 A  shows that specific binding to mock and 
L-endoglin transfectants was similarly increased in a dose- 
dependent  manner,  whereas  binding  to  S-endoglin  ex- 
pressing cells was slightly increased (up to 150% at 250 pM), 
with respect to mock cells. This was confirmed in four dif- 
ferent experiments. Next, the identification of the receptors 
bound to TGF-[31 in the U-937 transfectants was measured 
by affinity labeling and chemical cross-linking at three dif- 
ferent concentrations of ligand (50, 150, and 250 pM). SDS- 
PAGE  analysis  of total  lysates revealed  a  major 70-kD 
band of the putative R-I, and additional bands of 100-120 
kD (likely R-II), 190-200 kD (endoglin), and high molecu- 
lar weight oligomers (Fig. 6 B). As a  control, L-endoglin 
(200 kD)  and  S-endoglin  (190  kD)  could  be  specifically 
immunoprecipitated from transfectants.  Interestingly, the 
putative R-I displayed a significant increase of ligand bind- 
ing in endoglin transfectants with respect to mock trans- 
fectants and  it was coimmunoprecipitated with endoglin. 
Overall, these results did not reveal a decreased binding to 
the signaling receptors and rule out that the loss of certain 
TGF-[3 responses in endoglin transfectants was due to de- 
ficient  ligand  binding.  Finally,  cell  associated  and  de- 
graded  (TCA  soluble)  radiolabeled  TGF-[3  were  deter- 
mined at different times of incubation at 37°C. As shown 
in Fig. 6 B, no significant differences were found between 
mock and endoglin transfectants in either the cell associ- 
ated or degraded TGF-[M, suggesting that the TGF-[3 deg- 
radation rate of endoglin transfectants cannot account for 
the loss of TGF-[3 responses. Further studies are needed to 
understand the mechanism of action of endoglin. 
Discussion 
The TGFq3 receptor system is composed of several mem- 
brane proteins which include the receptors type I  and II, 
Lastres et al_ Endoglin Modulates Cellular Responses to TGF-[3  1117 Figure 6.  Effect of endoglin expression on TGF-f31 binding and degradation. (A) Binding of 125I-TGF-131  to U-937 transfectants. U-937 
transfectants (7 ×  106 cells/sample)  expressing S-endoglin (S-Endo), L-endoglin (L-Endo), and mock transfectants (Mock), were incu- 
bated for 4 h at 4°C with 25-250 pM 125I-TGF-131  and washed as described in Materials and Methods. The nonspecific binding observed 
in the presence of a 40-fold excess unlabeled TGF-f31 was subtracted from the total cpm bound, to calculate the specific binding,  and ex- 
pressed as cpm bound per 106 ceils. (B) Identification of the TGF-f31 receptors present on U-937 endoglin transfectants. U-937 transfec- 
tants expressing L-endoglin (L-Endo) or S-endoglin (S-Endo) and mock transfectants (Mock) cells were affinity labeled by incubation 
with 50, 150, or 250 pM of 125I-TGF-IM,  followed by chemical cross-linking  with disuccinimidyl  suberate. Cell extracts corresponding to 
the incubation at 250 pM 125I-TGF-131  either in the absence (-) or in the presence (+) of a 50-fold excess unlabeled TGF-131, were im- 
munoprecipitated with anti-endoglin mAb. Total extracts and immunoprecipitates were analyzed by SDS-PAGE ona 7.5% acrylamide 
gel under nonreducing conditions. Radiolabeled receptors were detected on the dried gel with a Phosphorlmager 410A. The positions 
of L-endoglin (200 kD), S-endoglin, (190 kD), putative R-I (70 kD) and R-II (100-120 kD), and oligomers (>200 kD) are indicated. (C) 
Degradation of 125I-TGF-131 bound to U-937 transfectants. U-937 transfectants expressing S-endoglin (S-Endo), L-endoglin (L-Endo), 
and mock transfectants (Mock) were incubated for 1 h at 37°C in the presence of 100 pM 125I-TGF-131.  After affinity labeling,  cells were 
washed with fresh medium and triplicate aliquots of cells (2.5 ×  106 each) were reincubated at 37°C for the time periods indicated. At 
the end of each time interval, cells were pelleted and the supernatants were collected. Supematant aliquots were precipitated with 10% 
TCA on ice. Cell-associated radioactivity, total radioactivity in supernatants, and TCA soluble radioactivity were estimated in a gamma 
counter. Percentages were calculated as described in Materials and Methods. The mean of triplicate samples --- SD is shown. 
betaglycan, and endoglin. The heteromeric  association of 
the  serine/threonine  kinase  receptors  I  and  II,  brought 
about by ligand  binding,  and the phosphorylation of R-I 
by R-II have been described as important elements in me- 
diating TGF-13 responses  (Franzen et al., 1993; Bassing et 
al., 1994; Wrana et al., 1994; Laiho et al.,  1991; Lin et al., 
1992; Wrana et al.,  1992; C~ircamo et al.,  1994; Koenig et 
al., 1994). Betaglycan has been shown previously to poten- 
tiate the binding of ligand to cells and both betaglycan and 
endoglin have been suggested to associate with the signal- 
ing complexes  (l_~pez-Casillas  et  al.,  1993; Moustakas  et 
al., 1993; Yamashita et al., 1994). In the current study, we 
demonstrate  that  endoglin  when  transfected  in  U-937 
cells, can alter specific responses of cells to TGF-IM, sug- 
gesting that it can modulate the signals transmitted by the 
receptor complex. 
That endoglin is a critical component of endothelial cells 
was demonstrated recently by the observation that muta- 
tions in the coding region of endoglin lead  to a  vascular 
disorder known as hereditary haemorrhagic telangiectasia 
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langiectases, pulmonary and cerebral arteriovenous mal- 
formations, and gastrointestinal bleeding (MacAllister et 
al., 1994). The role of endoglin in hemopoietic cells is un- 
known. Its expression is restricted to a subset of erythroid 
progenitors in both adult and fetal marrow, and more re- 
cently, to subpopulations  of pre-B ceils in fetal marrow 
(Biihring et al., 1991; Rokhlin et al.,  1995). Monocytes in 
culture and tissue macrophages also express endoglin, sug- 
gesting that it might play a specific role in the specialized 
function of these ceils (Lastres et al., 1992; O'Connell et 
al., 1992). 
Here, we have analyzed the role and regulated expres- 
sion of endoglin in monocytic cells. To our surprise, TGF-13 
was found to upregulate the  expression of endoglin not 
only on U-937 cells, but also on peripheral blood mono- 
cytes. Furthermore, the upregulation of endoglin on pe- 
ripheral blood monocytes in culture can be abolished by a 
neutralizing antibody to TGF-131, even in the absence of 
serum, suggesting that release of active ligand by mono- 
cytes might stimulate their expression of endoglin by an 
autocrine-like mechanism. We also observed that TGF-131 
not only increases the expression of endoglin, but also that 
of  R-l,  R-II,  and  betaglycan,  suggesting  that  common 
mechanisms might govern the regulation of expression of 
the  different TGF-[3 receptors.  It  remains  to  be  deter- 
mined  if the  increased  mRNA  expression is  associated 
with a higher transcription rate or increased message sta- 
bility. Higher levels of all four receptors were detected at 
the  surface of U-937  cells which  had been treated with 
ligand 72 h before cross-linking experiments with radiola- 
beled TGF-[31 (Lastres, P., unpublished data). A  similar 
upregulation of TGF-13 receptors might occur upon activa- 
tion of monocytes in vivo at sites of inflammation or injury 
which would lead to further amplification of the response 
to TGF-13 generally released at these sites. 
We chose to transfect U-937 cells with endoglin to gain 
some understanding of its potential effects on the response 
of these monocytic cells to TGF-13  (Table II). Endoglin, 
which binds  the  [31- but not the  132-isoform,  specifically 
blocked the inhibitory action of TGF-131 on proliferation 
of U-937 transfectants. Downregulation of c-myc, which is 
associated with an arrest in cell cycle, was not observed in 
the L-endoglin transfectants. Furthermore, the basal level 
of c-myc was increased by twofold, suggesting that endoglin 
was interfering with proliferation inhibition by preventing 
the downregulation of c-myc. This is in agreement with the 
finding that overexpression of c-myc blocks the growth in- 
hibitory response to TGF-131  (Alexandrow et al.,  1995). 
S-Endogtin was less efficient in blocking the inhibitory ef- 
fects of TGF-131 on cell growth and an increase in the basal 
level of c-myc, similar to that seen in the L-endoglin trans- 
fectants,  was  observed  in  the  S-endoglin  transfectants; 
however, a certain decrease in the level of c-myc could be 
observed upon addition of ligand. The only difference be- 
tween S-endoglin and L-endoglin is a shorter cytoplasmic 
domain and a lower level of serine/threonine phosphoryla- 
tion of S-endoglin. Thus, the differences observed in the 
biological responses of both isoforms suggest an important 
role of the cytoplasmic region in endoglin function. In this 
sense, it is interesting to note that TGF-[31 is able to inhibit 
the constitutive phosphorylation of endoglin  (Lastres et 
al., 1994). As the cytoplasmic domains of endoglin and be- 
taglycan are highly conserved (Gougos and Letarte, 1990; 
Mor6n et al., 1992), these two proteins are likely to have 
similar mediators. 
The presence of endoglin was also able to inhibit the in- 
crease in fibronectin synthesis and in the fibronectin-depen- 
dent cell adhesion  seen in response to TGF-13.  Further- 
more, phosphorylation of PECAM-1  and the subsequent 
homotypic aggregation of these cells, were also inhibited 
by endoglin expression. By contrast, other biological re- 
sponses to TGF-[3 such as the upregulation of TGF-[3 re- 
ceptors (R-I, R-II, and betaglycan), changes in the expression 
of integrins  (a4[~l and  a5131) and  of adhesion  proteins, 
members of the immunoglobulin superfamily (PECAM-1 
and ICAM-1) were not altered in the endoglin transfec- 
tants. The distinct cellular responses observed suggest the 
existence of a mechanism of signal transduction finely reg- 
ulated downstream of the R-I/R-II complex. The complex- 
ity of the TGF-13  responses is  such that one should not 
conclude that endoglin is always inhibitory. The interac- 
tions among TGF-[3 isoforms, modulators (betaglycan and 
endoglin),  signalers  (R-I  and  R-II),  and  probably addi- 
tional components of the receptor and signaling systems, 
could account for the pleiotropic effects of TGF-[3 (Wahl, 
1994; Moses et al., 1990). 
Our studies clearly demonstrate that endoglin can mod- 
ulate several of the responses to TGF-[31 and is thus an in- 
tegral component of the receptor system. The exact molec- 
ular  mechanism  of  action  of  endoglin  remains  to  be 
determined. Coimmunoprecipitation in affinity labeled pig 
endothelial cells and human  leukemic cells of endoglin, 
R-II, and R-I suggests that such a complex is formed (Ya- 
mashita et al., 1994; Zhang et al., 1996). We have also seen 
these  heteromeric associations  in  human  umbilical vein 
Table I1. Effects of Endoglin Overexpression  on Cellular 
Responses Induced by TGF-131 
Biological response  U937/Mock  L-Endoglin  S-Endoglin 
Growth inhibition  Yes  No  Minimal 
c-myc 
Basal level  Increased  Increased 
Downregulation  Yes  No  Partial 
Stimulation 
Fibronectin synthesis  Yes  No  No 
Cellular adhesion  Yes  No  No 
PECAM- 1 phosphorylation  Yes  No  No 
Homotypic aggregation  Yes  No  No 
Stimulation 
PECAM- 1 expression  Yes  Yes  Yes 
e5131 integrin expression  Yes  Yes  Yes 
Reduction 
a413~ integrin expression  Yes  Yes  Yes 
ICAM-t expression  Yes  Yes  Yes 
Stimulation of mRNA levels 
TGF-131 (13-20-fold)  Yes  Yes  Yes 
R-I, R-II, and betaglycan 
(5-20-fold)  Yes  Yes  Yes 
Specific transcripts ofc-myc were stimated by Northern blot analysis. Surface expres- 
sion of PECAM-1, et413  ~, a~13~, and ICAM-I were estimated by flow cytometry and 
levels of mRNA for TGF-131 and TGF-13 receptors were estimated by quantitative PCR. 
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the presence of a putative R-I coimmunoprecipitated with 
endoglin and the increased ligand binding to this receptor, 
point to an active  role of endoglin  in these  heteromeric 
complexes. It can be postulated that this association with 
the signaling receptors might confer to endoglin the ability 
to bind TGF-~3. This could explain that in endothelial cells, 
where endoglin expression is high (106 molecules per cell), 
in contrast with the low expression of signaling receptors 
(104 molecules per cell), only a small number of endoglin 
molecules bind TGF-13 (Cheifetz et al., 1992).  Unlike en- 
doglin, betaglycan readily binds TGF-13 even in its soluble 
form (L6pez-Casillas et al., 1991), suggesting that endoglin 
has a mechanism of action different from betaglycan. This 
hypothesis is in agreement with the lack of growth inhibi- 
tory response of TGF-I~ in endoglin transfectants, whereas 
transfection of betaglycan  confers increased inhibition of 
proliferation in the presence of ligand (L6pez-Casillas et 
al.,  1991).  Also,  these  counteracting  effects  of endoglin 
and betaglycan might be compatible with the almost non- 
overlapping  expression  of these  two proteins  in  several 
cell types. 
Our results suggest that endoglin functions as an auxil- 
iary receptor which contributes to the complex regulation 
of TGF-13 responses. 
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